Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Csl Ltd (CSLLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 30,971,168
  • Shares Outstanding, K 452,398
  • Annual Sales, $ 7,915 M
  • Annual Income, $ 1,729 M
  • 60-Month Beta 0.81
  • Price/Sales 3.96
  • Price/Cash Flow 18.11
  • Price/Book 7.67
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 10/02/18
  • Annual Dividend & Yield 0.76 (1.11%)
  • Most Recent Dividend 0.380 on 03/14/19
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.6040 +1.27%
on 03/20/19
72.4200 -5.47%
on 04/10/19
-1.6450 (-2.35%)
since 03/18/19
3-Month
65.2600 +4.90%
on 02/15/19
72.4200 -5.47%
on 04/10/19
-2.7250 (-3.83%)
since 01/18/19
52-Week
60.5100 +13.14%
on 04/23/18
83.1200 -17.64%
on 08/30/18
+6.1650 (+9.90%)
since 04/18/18

Most Recent Stories

More News
Global Antidiuretic Drugs Market 2019-2023 with Avadel, CSL Limited, Ferring B.V., Novartis & Sanofi Dominating

The "Global Antidiuretic Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

NVS : 76.41 (-1.15%)
CSLLY : 68.4600 (-1.07%)
Japan's Ministry of Health, Labour and Welfare Approves CSL Behring Immunoglobulins to Treat Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

TOKYO , March 26, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that Japan's Ministry of Health, Labour and Welfare has approved two of its immunoglobulin...

CSLLY : 68.4600 (-1.07%)
CSL Behring Extends Support of World Federation of Hemophilia Programs

Reinforces Commitment to Providing Global Bleeding Disorders Community with Access to Care and Efforts to Increase Awareness

CSLLY : 68.4600 (-1.07%)
CSL Named One of the Best Employers in the US for Diversity

KING OF PRUSSIA, Pa. , Jan. 16, 2019 /PRNewswire/ -- Forbes magazine has named global biotechnology leader CSL Limited as one of The Best Employers for Diversity in the United States . CSL,...

CSLLY : 68.4600 (-1.07%)
Hemophilia Association Of New Jersey Recognizes CSL CEO Paul Perreault As "Humanitarian Man Of The Year"

CEO and Managing Director of CSL Limited Paul Perreault has been named "Humanitarian Man of the Year" by the Hemophilia Association of New Jersey (HANJ). HANJ President David Lechner presented the award...

CSLLY : 68.4600 (-1.07%)
Patient Advocacy Groups Focus On Key Issues Affecting Patients

Patient advocacy groups in Michigan, Washington, Illinois, Missouri and South Carolina are preparing to meet the many challenges standing between patients with rare bleeding disorders and access to care....

CSLLY : 68.4600 (-1.07%)
Patient Advocacy Groups Focus On Key Issues Affecting Patients

KING OF PRUSSIA, Pa. , April 26, 2018 /PRNewswire/ -- Patient advocacy groups in Michigan , Washington , Illinois , Missouri and South Carolina are preparing to meet the many...

CSLLY : 68.4600 (-1.07%)
CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting

KING OF PRUSSIA, Pa. , April 20, 2018 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that it will host an Industry Therapeutic Update at the 2018 annual meeting of the...

CSLLY : 68.4600 (-1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade CSLLY with:

Key Turning Points

2nd Resistance Point 69.0267
1st Resistance Point 68.7433
Last Price 68.4600
1st Support Level 68.1733
2nd Support Level 67.8867

See More

52-Week High 83.1200
Fibonacci 61.8% 74.4830
Fibonacci 50% 71.8150
Fibonacci 38.2% 69.1470
Last Price 68.4600
52-Week Low 60.5100

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar